# Core Task
Analyze the literature to classify the primary therapeutic effect of the natural product-based drug combination into one of three categories: (1) enhancing drug efficacy by augmenting sensitivity and achieving synergy, (2) decreasing adverse drug reactions, or (3) reversing drug resistance.
Literature to analyze: `dataset\NPCDR\27980427.pdf`, `dataset\NPCDR\25653233.pdf`, `dataset\NPCDR\23429291.pdf`, `dataset\NPCDR\21088503.pdf`, `dataset\NPCDR\32872376.pdf`, `dataset\NPCDR\29626307.pdf`

# Output Requirements & File Path
- Output format: A JSON list of dictionaries with "PMID" and "TypeID". 
- "PMID" is the filename, and "TypeID" is the classification category mentioned above (int).
- Save Path: Save the complete list to: `/root/autodl-tmp/biomni_v20260208_pred_results/gemini-3-pro-preview/npcdr_extract_1.json`
- Intermediate Storage Path: All intermediate code generated during execution, downloaded files, and temporary results must be stored in `/root/autodl-tmp/biomni_v20260208_tmp/gemini-3-pro-preview/npcdr_extract_1/`

# Example Output (For Reference Only)
[
  {
      "PMID": "15380427",
      "TypeID": 2
  },
  {
      "PMID": "25653532",
      "TypeID": 1
  }
]

I will start by analyzing the provided literature to classify the therapeutic effects of the drug combinations.

Here is the plan:
1. [ ] Create the intermediate directory `/root/autodl-tmp/biomni_v20260208_tmp/gemini-3-pro-preview/npcdr_extract_1/`.
2. [ ] Read the text content from each of the 6 PDF files (`dataset\NPCDR\27980427.pdf`, `dataset\NPCDR\25653233.pdf`, `dataset\NPCDR\23429291.pdf`, `dataset\NPCDR\21088503.pdf`, `dataset\NPCDR\32872376.pdf`, `dataset\NPCDR\29626307.pdf`).
3. [ ] Analyze the text of each paper to determine the primary therapeutic effect based on the three categories. I will look for keywords related to "synergy/enhancing efficacy", "toxicity/adverse effects/side effects", and "resistance/reversal".
4. [ ] Construct the final JSON list.
5. [ ] Save the JSON list to `/root/autodl-tmp/biomni_v20260208_pred_results/gemini-3-pro-preview/npcdr_extract_1.json`.

Let's start by creating the directory and checking the files.

<execute>
#!BASH
mkdir -p /root/autodl-tmp/biomni_v20260208_tmp/gemini-3-pro-preview/npcdr_extract_1/
mkdir -p /root/autodl-tmp/biomni_v20260208_pred_results/gemini-3-pro-preview/

# List the files to confirm their existence and paths
ls -F dataset/NPCDR/27980427.pdf dataset/NPCDR/25653233.pdf dataset/NPCDR/23429291.pdf dataset/NPCDR/21088503.pdf dataset/NPCDR/32872376.pdf dataset/NPCDR/29626307.pdf</execute>
<observation>Error running Bash script (exit code 2):
ls: cannot access 'dataset/NPCDR/27980427.pdf': No such file or directory
ls: cannot access 'dataset/NPCDR/25653233.pdf': No such file or directory
ls: cannot access 'dataset/NPCDR/23429291.pdf': No such file or directory
ls: cannot access 'dataset/NPCDR/21088503.pdf': No such file or directory
ls: cannot access 'dataset/NPCDR/32872376.pdf': No such file or directory
ls: cannot access 'dataset/NPCDR/29626307.pdf': No such file or directory
</observation>
I will search for the files to identify the correct paths.

1. [ ] Create the intermediate directory `/root/autodl-tmp/biomni_v20260208_tmp/gemini-3-pro-preview/npcdr_extract_1/`.
2. [ ] Locate the PDF files.
3. [ ] Read the text content from each of the 6 PDF files.
4. [ ] Analyze the text of each paper to determine the primary therapeutic effect.
5. [ ] Construct the final JSON list.
6. [ ] Save the JSON list.

<execute>
#!BASH
find . -name "27980427.pdf"
find . -name "25653233.pdf"
find / -name "27980427.pdf" 2>/dev/null</execute>
<observation>Error running Bash script (exit code 1):
</observation>
I will start by listing the current directory and checking if the `dataset` folder exists to locate the files.

<execute>
#!BASH
ls -R</execute>
<observation>The output is too long to be added to context. Here are the first 10K characters...
.:
ANARCI
README.md
assistant
benchmark
cache
data
elton_birds_species_list.csv
env_install.sh
environment.yaml
environment.yml
evaluate_bash_scripts
evaluate_results
example_log_trajectory.json
example_log_trajectory_zjt.json
expression_analyses
log
mapper_logs
ncbi_dataset.zip
operation_env
paper_analysis
pdfs_mysample
pdfs_sample
pred_results
run_evaluate_batch_biomni.py
run_evaluate_batch_biomni.sh
run_evaluate_batch_biomni_for_bash.py
run_evaluate_case_biomni.py
run_evaluate_case_stella.py
run_evaluate_case_tooluniverse.py
run_only_evaluate.py
sample_metadata_extracted.csv
traitdata

./ANARCI:
Example_scripts_and_sequences
INSTALL
LICENCE
LICENCE_MUSCLE
README.md
anarci.egg-info
bin
build
build_pipeline
lib
requirements.txt
setup.py

./ANARCI/Example_scripts_and_sequences:
12e8.fasta
ImmunoPDB.py
anarci_API_example.py
antibody_sequences.fasta
lysozyme.fasta
pdb_sequences.fa.txt.gz
run_numbering_benchmark.sh

./ANARCI/anarci.egg-info:
PKG-INFO
SOURCES.txt
dependency_links.txt
top_level.txt

./ANARCI/bin:
ANARCI
muscle
muscle_macOS

./ANARCI/build:
bdist.linux-x86_64
lib
scripts-3.11

./ANARCI/build/bdist.linux-x86_64:
wheel

./ANARCI/build/bdist.linux-x86_64/wheel:
anarci
anarci-1.3-py3.11.egg-info
anarci-1.3.data

./ANARCI/build/bdist.linux-x86_64/wheel/anarci:
__init__.py
anarci.py
schemes.py

./ANARCI/build/bdist.linux-x86_64/wheel/anarci-1.3-py3.11.egg-info:
PKG-INFO
SOURCES.txt
dependency_links.txt
top_level.txt

./ANARCI/build/bdist.linux-x86_64/wheel/anarci-1.3.data:
data
scripts

./ANARCI/build/bdist.linux-x86_64/wheel/anarci-1.3.data/data:
bin

./ANARCI/build/bdist.linux-x86_64/wheel/anarci-1.3.data/data/bin:
ANARCI
muscle
muscle_macOS

./ANARCI/build/bdist.linux-x86_64/wheel/anarci-1.3.data/scripts:
ANARCI

./ANARCI/build/lib:
anarci

./ANARCI/build/lib/anarci:
__init__.py
anarci.py
schemes.py

./ANARCI/build/scripts-3.11:
ANARCI

./ANARCI/build_pipeline:
FastaIO.py
FastaIO.pyc
FormatAlignments.py
HMMs
IMGT_sequence_files
RUN_pipeline.sh
RipIMGT.py
__init__.py
__pycache__
curated_alignments
muscle_alignments
test.csv_H.csv

./ANARCI/build_pipeline/HMMs:
ALL.hmm
ALL.hmm.h3f
ALL.hmm.h3i
ALL.hmm.h3m
ALL.hmm.h3p

./ANARCI/build_pipeline/IMGT_sequence_files:
fastafiles
htmlfiles

./ANARCI/build_pipeline/IMGT_sequence_files/fastafiles:
Bos_taurus_HJ.fasta
Bos_taurus_HV.fasta
Bos_taurus_KJ.fasta
Bos_taurus_KV.fasta
Bos_taurus_LJ.fasta
Bos_taurus_LV.fasta
Homo_sapiens_AJ.fasta
Homo_sapiens_AV.fasta
Homo_sapiens_BJ.fasta
Homo_sapiens_BV.fasta
Homo_sapiens_DJ.fasta
Homo_sapiens_DV.fasta
Homo_sapiens_GJ.fasta
Homo_sapiens_GV.fasta
Homo_sapiens_HJ.fasta
Homo_sapiens_HV.fasta
Homo_sapiens_KJ.fasta
Homo_sapiens_KV.fasta
Homo_sapiens_LJ.fasta
Homo_sapiens_LV.fasta
Macaca_mulatta_HJ.fasta
Macaca_mulatta_HV.fasta
Macaca_mulatta_KJ.fasta
Macaca_mulatta_KV.fasta
Macaca_mulatta_LJ.fasta
Macaca_mulatta_LV.fasta
Mus_AJ.fasta
Mus_AV.fasta
Mus_BJ.fasta
Mus_BV.fasta
Mus_DJ.fasta
Mus_DV.fasta
Mus_GJ.fasta
Mus_GV.fasta
Mus_HJ.fasta
Mus_HV.fasta
Mus_KJ.fasta
Mus_KV.fasta
Mus_LJ.fasta
Mus_LV.fasta
Oryctolagus_cuniculus_HJ.fasta
Oryctolagus_cuniculus_HV.fasta
Oryctolagus_cuniculus_KJ.fasta
Oryctolagus_cuniculus_KV.fasta
Oryctolagus_cuniculus_LJ.fasta
Oryctolagus_cuniculus_LV.fasta
Rattus_norvegicus_HJ.fasta
Rattus_norvegicus_HV.fasta
Rattus_norvegicus_KJ.fasta
Rattus_norvegicus_KV.fasta
Rattus_norvegicus_LJ.fasta
Rattus_norvegicus_LV.fasta
Sus_scrofa_HJ.fasta
Sus_scrofa_HV.fasta
Sus_scrofa_KJ.fasta
Sus_scrofa_KV.fasta
Sus_scrofa_LJ.fasta
Sus_scrofa_LV.fasta
Vicugna_pacos_HJ.fasta
Vicugna_pacos_HV.fasta

./ANARCI/build_pipeline/IMGT_sequence_files/htmlfiles:
Bos_taurus_HJ.html
Bos_taurus_HV.html
Bos_taurus_KJ.html
Bos_taurus_KV.html
Bos_taurus_LJ.html
Bos_taurus_LV.html
Homo_sapiens_AJ.html
Homo_sapiens_AV.html
Homo_sapiens_BJ.html
Homo_sapiens_BV.html
Homo_sapiens_DJ.html
Homo_sapiens_DV.html
Homo_sapiens_GJ.html
Homo_sapiens_GV.html
Homo_sapiens_HJ.html
Homo_sapiens_HV.html
Homo_sapiens_KJ.html
Homo_sapiens_KV.html
Homo_sapiens_LJ.html
Homo_sapiens_LV.html
Macaca_mulatta_HJ.html
Macaca_mulatta_HV.html
Macaca_mulatta_KJ.html
Macaca_mulatta_KV.html
Macaca_mulatta_LJ.html
Macaca_mulatta_LV.html
Mus_AJ.html
Mus_AV.html
Mus_BJ.html
Mus_BV.html
Mus_DJ.html
Mus_DV.html
Mus_GJ.html
Mus_GV.html
Mus_HJ.html
Mus_HV.html
Mus_KJ.html
Mus_KV.html
Mus_LJ.html
Mus_LV.html
Oryctolagus_cuniculus_HJ.html
Oryctolagus_cuniculus_HV.html
Oryctolagus_cuniculus_KJ.html
Oryctolagus_cuniculus_KV.html
Oryctolagus_cuniculus_LJ.html
Oryctolagus_cuniculus_LV.html
Rattus_norvegicus_HJ.html
Rattus_norvegicus_HV.html
Rattus_norvegicus_KJ.html
Rattus_norvegicus_KV.html
Rattus_norvegicus_LJ.html
Rattus_norvegicus_LV.html
Sus_scrofa_HJ.html
Sus_scrofa_HV.html
Sus_scrofa_KJ.html
Sus_scrofa_KV.html
Sus_scrofa_LJ.html
Sus_scrofa_LV.html
Vicugna_pacos_HJ.html
Vicugna_pacos_HV.html

./ANARCI/build_pipeline/__pycache__:
FastaIO.cpython-311.pyc

./ANARCI/build_pipeline/curated_alignments:
ALL.stockholm
alpaca_H.stockholm
cow_H.stockholm
cow_K.stockholm
cow_L.stockholm
germlines.py
human_A.stockholm
human_B.stockholm
human_D.stockholm
human_G.stockholm
human_H.stockholm
human_K.stockholm
human_L.stockholm
mouse_A.stockholm
mouse_B.stockholm
mouse_D.stockholm
mouse_G.stockholm
mouse_H.stockholm
mouse_K.stockholm
mouse_L.stockholm
pig_H.stockholm
pig_K.stockholm
pig_L.stockholm
rabbit_H.stockholm
rabbit_K.stockholm
rabbit_L.stockholm
rat_K.stockholm
rat_L.stockholm
rhesus_H.stockholm
rhesus_K.stockholm
rhesus_L.stockholm

./ANARCI/build_pipeline/muscle_alignments:
all_js.fasta
all_js_aligned.fasta

./ANARCI/lib:
python

./ANARCI/lib/python:
anarci

./ANARCI/lib/python/anarci:
__init__.py
__pycache__
anarci.py
schemes.py

./ANARCI/lib/python/anarci/__pycache__:
__init__.cpython-311.pyc
anarci.cpython-311.pyc
schemes.cpython-311.pyc

./assistant:
__init__.py
__pycache__
agent
biorxiv_scripts
commons
env_desc_biodatalab.py
env_desc_biomni.py
interface.py
llm.py
model
prompts
task
tool_biodatalab
tool_biomni
utils.py
version.py

./assistant/__pycache__:
__init__.cpython-311.pyc
__init__.cpython-312.pyc
env_desc.cpython-311.pyc
env_desc_biodatalab.cpython-311.pyc
llm.cpython-311.pyc
utils.cpython-311.pyc
version.cpython-311.pyc
version.cpython-312.pyc

./assistant/agent:
__init__.py
__pycache__
a1.py
a1_ref.py
cost_count.py
env_collection.py
qa_llm.py
react.py

./assistant/agent/__pycache__:
__init__.cpython-311.pyc
__init__.cpython-312.pyc
a1.cpython-311.pyc
a1.cpython-312.pyc
a1_ref.cpython-311.pyc
cost_count.cpython-311.pyc

./assistant/biorxiv_scripts:
extract_biorxiv_tasks.py
generate_function.py
generation_tools_all_subjects.py
process_all_subjects.py

./assistant/commons:
__pycache__
utils.py

./assistant/commons/__pycache__:
utils.cpython-311.pyc

./assistant/model:
__init__.py
__pycache__
retriever_biodatalab.py
retriever_biomni.py

./assistant/model/__pycache__:
__init__.cpython-311.pyc
retriever.cpython-311.pyc
retriever_biodatalab.cpython-311.pyc

./assistant/prompts:
help_create_benchmark_task.txt
help_summary_one_paper_database_and_tools.txt
prompt.md
summary_domain_database_and_tools.txt
summary_domain_database_and_tools_merge.txt

./assistant/task:
__init__.py
__pycache__
base_task.py
hle.py
lab_bench.py

./assistant/task/__pycache__:
__init__.cpython-311.pyc

./assistant/tool_biodatalab:
__pycache__
database.py
database_tools.py
structure_tools.py
support_tools.py
tool_description
tool_registry.py

./assistant/tool_biodatalab/__pycache__:
database.cpython-311.pyc
database_tools.cpython-311.pyc
structure_tools.cpython-311.pyc
support_tools.cpython-311.pyc
tool_registry.cpython-311.pyc

./assistant/tool_biodatalab/tool_description:
__pycache__
database.py
database_tools.py
structure_tools.py
support_tools.py

./assistant/tool_biodatalab/tool_description/__pycache__:
support_tools.cpython-311.pyc

./assistant/tool_biomni:
__init__.py
__pycache__
biochemistry.py
bioengineering.py
biophysics.py
cancer_biology.py
cell_biology.py
database.py
example_mcp_tools
genetics.py
genomics.py
immunology.py
literature.py
microbiology.py
molecular_biology.py
pathology.py
pharmacology.py
physiology.py
schema_db
support_tools.py
synthetic_biology.py
systems_biology.py
tool_description
tool_registry.py

./assistant/tool_biomni/__pycache__:
__init__.cpython-311.pyc
database.cpython-311.pyc
literature.cpython-311.pyc
support_tools.cpython-311.pyc
tool_registry.cpython-311.pyc

./assistant/tool_biomni/example_mcp_tools:
pubmed_mcp.py

./assistant/tool_biomni/schema_db:
cbioportal.pkl
clinvar.pkl
dbsnp.pkl
emdb.pkl
ensembl.pkl
geo.pkl
gnomad.pkl
gtopdb.pkl
gwas_catalog.pkl
interpro.pkl
iucn.pkl
jaspar.pkl
kegg.pkl
monarch.pkl
mpd.pkl
openfda.pkl
opentarget.pkl
opentarget_genetics.pkl
paleobiology.pkl
pdb.pkl
pride.pkl
reactome.pkl
remap.pkl
stringdb.pkl
ucsc.pkl
uniprot.pkl
worms.pkl

./assistant/tool_biomni/tool_description:
__pycache__
biochemistry.py
bioengineering.py
biophysics.py
cancer_biology.py
cell_biology.py
database.py
genetics.py
genomics.py
immunology.py
literature.py
microbiology.py
molecular_biology.py
pathology.py
pharmacology.py
physiology.py
support_tools.py
synthetic_biology.py
systems_biology.py

./assistant/tool_biomni/tool_description/__pycache__:
biochemistry.cpython-311.pyc
bioengineering.cpython-311.pyc
biophysics.cpython-311.pyc
cancer_biology.cpython-311.pyc
cell_biology.cpython-311.pyc
database.cpython-311.pyc
genetics.cpython-311.pyc
genomics.cpython-311.pyc
immunology.cpython-311.pyc
literature.cpython-311.pyc
microbiology.cpython-311.pyc
molecular_biology.cpython-311.pyc
pathology.cpython-311.pyc
pharmacology.cpython-311.pyc
physiology.cpython-311.pyc
support_tools.cpython-311.pyc
synthetic_biology.cpython-311.pyc
systems_biology.cpython-311.pyc

./benchmark:
README.md
biodatalab.csv
biodatalab_new.csv
dataset
gold_programs
gold_results
tasks
update_verified_tasks.py
verified_task.json
verifiers

./benchmark/dataset:
ADCdb
ASMdb
ATLAS
BioKA
COLOCdb
COVID-19
CancerMIRNome
CancerProteome
CancerSCEM
CellCommuNet
CellSTAR
ClinicalOmicsDB
CompoDynamics
CovPD</observation>
I will search for the files in the `benchmark/dataset/NPCDR` directory.

1. [✓] Create the intermediate directory `/root/autodl-tmp/biomni_v20260208_tmp/gemini-3-pro-preview/npcdr_extract_1/`.
2. [ ] Locate the PDF files.
3. [ ] Read the text content from each of the 6 PDF files.
4. [ ] Analyze the text of each paper to determine the primary therapeutic effect.
5. [ ] Construct the final JSON list.
6. [ ] Save the JSON list.

<execute>
#!BASH
ls -F benchmark/dataset/NPCDR/27980427.pdf benchmark/dataset/NPCDR/25653233.pdf benchmark/dataset/NPCDR/23429291.pdf benchmark/dataset/NPCDR/21088503.pdf benchmark/dataset/NPCDR/32872376.pdf benchmark/dataset/NPCDR/29626307.pdf</execute>
<observation>benchmark/dataset/NPCDR/21088503.pdf
benchmark/dataset/NPCDR/23429291.pdf
benchmark/dataset/NPCDR/25653233.pdf
benchmark/dataset/NPCDR/27980427.pdf
benchmark/dataset/NPCDR/29626307.pdf
benchmark/dataset/NPCDR/32872376.pdf
</observation>
I will now run the Python script to read the PDFs, classify the therapeutic effects, and save the results.

<execute>
import pdfplumber
import os
import json
import re

# Define paths
data_dir = "benchmark/dataset/NPCDR"
output_dir = "/root/autodl-tmp/biomni_v20260208_pred_results/gemini-3-pro-preview/"
output_file = os.path.join(output_dir, "npcdr_extract_1.json")
temp_dir = "/root/autodl-tmp/biomni_v20260208_tmp/gemini-3-pro-preview/npcdr_extract_1/"

# Ensure output directory exists
os.makedirs(output_dir, exist_ok=True)
os.makedirs(temp_dir, exist_ok=True)

files = [
    "27980427.pdf",
    "25653233.pdf",
    "23429291.pdf",
    "21088503.pdf",
    "32872376.pdf",
    "29626307.pdf"
]

results = []

def get_classification(text):
    text = text.lower()
    
    # Keywords for Category 1: Enhancing efficacy / Synergy
    keywords_1 = [
        "synerg", "combin", "enhanc", "sensit", "augment", "potentiat", "ci < 1", "combination index"
    ]
    
    # Keywords for Category 2: Decreasing adverse reactions / Toxicity
    keywords_2 = [
        "toxic", "adverse", "side effect", "nephrotox", "cardiotox", "hepatotox", "protect", "reduc", "damage", "injury", "attenuat"
    ]
    
    # Keywords for Category 3: Reversing drug resistance
    keywords_3 = [
        "resistan", "revers", "mdr", "efflux", "p-gp", "multidrug", "sensitiz", "overcom"
    ]

    # Simple scoring (this is a heuristic, real NLP would be better but this is a constrained environment)
    score_1 = sum(text.count(k) for k in keywords_1)
    score_2 = sum(text.count(k) for k in keywords_2)
    score_3 = sum(text.count(k) for k in keywords_3)
    
    # Adjust weights - "resistance" is very specific. "Synergy" is also specific.
    # "Toxicity" papers often have very strong keywords like "protective effect".
    
    # Refined logic: check title/abstract first if possible (usually first page)
    # But here we just use the whole text with specific phrases.
    
    # Specific checks for strong indicators
    if "reversal of" in text or "reversing" in text or "multidrug resistance" in text:
        score_3 += 20
    if "synergistic" in text or "synergism" in text:
        score_1 += 10
    if "protective effect" in text or "attenuates" in text or "ameliorates" in text:
        score_2 += 20

    print(f"Scores - Type 1: {score_1}, Type 2: {score_2}, Type 3: {score_3}")
    
    if score_3 > score_1 and score_3 > score_2:
        return 3
    elif score_2 > score_1 and score_2 > score_3:
        return 2
    else:
        return 1

for filename in files:
    filepath = os.path.join(data_dir, filename)
    print(f"Processing {filename}...")
    
    try:
        text_content = ""
        with pdfplumber.open(filepath) as pdf:
            # Read first few pages as they contain the most relevant info (Abstract, Intro)
            for page in pdf.pages[:3]: 
                text = page.extract_text()
                if text:
                    text_content += text + " "
        
        # If text is too short, try OCR or just read more pages? 
        # For now, assume pdfplumber works.
        
        # Clean text
        text_content = text_content.replace('\n', ' ')
        
        # Classify
        classification = get_classification(text_content)
        
        # Specific override logic based on manual inspection simulation or strong keywords
        # 1. 27980427: "Synergistic effect..." -> likely 1
        # 2. 25653233: "Reversal of..." -> likely 3
        # 3. 23429291: "...attenuates...toxicity" -> likely 2
        # Let's see what the scorer does, but I will log the extracted snippet to be sure.
        
        print(f"File: {filename}, Predicted Type: {classification}")
        print(f"Snippet: {text_content[:200]}...")

        results.append({
            "PMID": filename.replace(".pdf", ""),
            "TypeID": classification
        })

    except Exception as e:
        print(f"Error processing {filename}: {e}")
        # Default to 1 if failed? or skip?
        results.append({
            "PMID": filename.replace(".pdf", ""),
            "TypeID": 1 # Default fallback
        })

# Save results
with open(output_file, 'w') as f:
    json.dump(results, f, indent=4)

print(f"Results saved to {output_file}")
print(json.dumps(results, indent=4))</execute>
<observation>Processing 27980427.pdf...
Scores - Type 1: 30, Type 2: 5, Type 3: 37
File: 27980427.pdf, Predicted Type: 3
Snippet: Journal name: OncoTargets and Therapy Article Designation: Original Research Year: 2016 Volume: 9 OncoTargets and Therapy Dovepress Running head verso: Kang et al Running head recto: Curcumin mediates...
Processing 25653233.pdf...
Scores - Type 1: 52, Type 2: 14, Type 3: 36
File: 25653233.pdf, Predicted Type: 1
Snippet: Carcinogenesis, 2015, Vol. 36, No. 3, 355–367 doi:10.1093/carcin/bgv006 Advance Access publication February 4, 2015 Original Manuscript original manuscript Curcumin mediates chemosensitization to 5-fl...
Processing 23429291.pdf...
Scores - Type 1: 69, Type 2: 17, Type 3: 47
File: 23429291.pdf, Predicted Type: 1
Snippet: Citation:CellDeathandDisease(2013)4,e505;doi:10.1038/cddis.2013.26 &2013MacmillanPublishersLimited Allrightsreserved 2041-4889/13 www.nature.com/cddis Mechanistic evaluation of the signaling events re...
Processing 21088503.pdf...
Scores - Type 1: 44, Type 2: 19, Type 3: 6
File: 21088503.pdf, Predicted Type: 1
Snippet: RESEARCH PAPER RESEARCH PAPER Cancer Biology & Therapy 11:2, 263-276; January 15, 2011; © 2011 Landes Bioscience Anticancer activity of celastrol in combination with ErbB2-targeted therapeutics for tr...
Processing 32872376.pdf...
Scores - Type 1: 2, Type 2: 43, Type 3: 1
File: 32872376.pdf, Predicted Type: 2
Snippet: nutrients Article Dietary Glycine Prevents FOLFOX Chemotherapy-Induced Heart Injury: A Colorectal Cancer Liver Metastasis Treatment Model in Rats JusteManeikyte1,2,AugustinasBausys1,2,3,BettinaLeber1 ...
Processing 29626307.pdf...
Scores - Type 1: 3, Type 2: 7, Type 3: 0
File: 29626307.pdf, Predicted Type: 2
Snippet: HHS Public Access Author manuscript Ann Surg Oncol. Author manuscript; available in PMC 2019 June 01. Published in final edited form as: Ann Surg Oncol. 2018 June ; 25(6): 1709–1715. doi:10.1245/s1043...
Results saved to /root/autodl-tmp/biomni_v20260208_pred_results/gemini-3-pro-preview/npcdr_extract_1.json
[
    {
        "PMID": "27980427",
        "TypeID": 3
    },
    {
        "PMID": "25653233",
        "TypeID": 1
    },
    {
        "PMID": "23429291",
        "TypeID": 1
    },
    {
        "PMID": "21088503",
        "TypeID": 1
    },
    {
        "PMID": "32872376",
        "TypeID": 2
    },
    {
        "PMID": "29626307",
        "TypeID": 2
    }
]
</observation>
I need to review the results, especially for the cases where the classification might be ambiguous or the scores were close.

**Analysis of the logs:**
*   **27980427.pdf**: Predicted Type 3. Scores: T1=30, T2=5, T3=37. The snippet mentions "Curcumin mediates...". Let's double check. If it's about reversing resistance, 3 is correct. If it's just sensitizing, it might be 1. The score difference is small.
*   **25653233.pdf**: Predicted Type 1. Scores: T1=52, T2=14, T3=36. Snippet: "Curcumin mediates chemosensitization to 5-flu...". Chemosensitization often overlaps with Type 1 (enhancing efficacy) and Type 3 (reversing resistance). If the cells are resistant, it's 3. If they are standard cells, it's 1. Score favors 1.
*   **23429291.pdf**: Predicted Type 1. Scores: T1=69, T2=17, T3=47. High score for 1. Snippet: "Mechanistic evaluation of the signaling events...".
*   **21088503.pdf**: Predicted Type 1. Scores: T1=44, T2=19, T3=6. Clear winner. Snippet: "Anticancer activity of celastrol in combination with ErbB2-targeted therapeutics". Likely synergy.
*   **32872376.pdf**: Predicted Type 2. Scores: T1=2, T2=43, T3=1. Clear winner. Snippet: "Dietary Glycine Prevents FOLFOX Chemotherapy-Induced Heart Injury". This is definitely toxicity reduction.
*   **29626307.pdf**: Predicted Type 2. Scores: T1=3, T2=7, T3=0. Low scores generally. Snippet: "HHS Public Access... Ann Surg Oncol". I need to be careful here.

I'll write a small script to read the titles and abstracts more specifically to confirm the classifications, especially for the "Sensitization vs Resistance" cases.

1. [✓] Create the intermediate directory `/root/autodl-tmp/biomni_v20260208_tmp/gemini-3-pro-preview/npcdr_extract_1/`.
2. [✓] Locate the PDF files.
3. [ ] Read the text content from each of the 6 PDF files (Refined check).
4. [ ] Analyze the text of each paper to determine the primary therapeutic effect (Refined check).
5. [ ] Construct the final JSON list.
6. [ ] Save the JSON list.

<execute>
import pdfplumber
import os

data_dir = "benchmark/dataset/NPCDR"
files = [
    "27980427.pdf",
    "25653233.pdf",
    "23429291.pdf",
    "21088503.pdf",
    "32872376.pdf",
    "29626307.pdf"
]

for filename in files:
    filepath = os.path.join(data_dir, filename)
    with pdfplumber.open(filepath) as pdf:
        first_page = pdf.pages[0].extract_text()
        print(f"--- {filename} ---")
        print(first_page[:800]) # Print first 800 chars to see Title/Abstract
        print("\n")</execute>
<observation>--- 27980427.pdf ---
Journal name: OncoTargets and Therapy
Article Designation: Original Research
Year: 2016
Volume: 9
OncoTargets and Therapy Dovepress Running head verso: Kang et al
Running head recto: Curcumin mediates chemosensitization to 5-FU
open access to scientific and medical research
DOI: http://dx.doi.org/10.2147/OTT.S118272
Open access Full Text article Original research
curcumin sensitizes human gastric cancer cells
to 5-fluorouracil through inhibition of the NFκB
survival-signaling pathway
Yanting Kang1,2,* Abstract: Fluorouracil (5-FU) is the most commonly used chemotherapeutic agent for gastric
Wanle hu3,* cancer (GC). However, the occurrence of resistance to 5-FU treatment poses a major problem
encheng Bai1,2 for its clinical efficacy. In this study, we found that the NFκB-signaling pathway c


--- 25653233.pdf ---
Carcinogenesis, 2015, Vol. 36, No. 3, 355–367
doi:10.1093/carcin/bgv006
Advance Access publication February 4, 2015
Original Manuscript
original manuscript
Curcumin mediates chemosensitization to 5-fluorouracil
through miRNA-induced suppression of epithelial-
to-mesenchymal transition in chemoresistant
colorectal cancer
Shusuke Toden, Yoshinaga Okugawa, Thomas Jascur, Dominik Wodarz1,2,
Natalia L. Komarova1,2, Constanze Buhrmann3, Mehdi Shakibaei3,
C. Richard Boland and Ajay Goel*
Center for Gastrointestinal Research, and Center for Epigenetics, Cancer Prevention and Cancer Genomics, Baylor Research
Institute and Sammons Cancer Center, Baylor University Medical Center, 3500 Gaston Avenue, Suite H-250, Dallas, TX 75246,
USA, 1Department of Ecology and Evolution and 2Department of Mathematic


--- 23429291.pdf ---
Citation:CellDeathandDisease(2013)4,e505;doi:10.1038/cddis.2013.26
&2013MacmillanPublishersLimited Allrightsreserved 2041-4889/13
www.nature.com/cddis
Mechanistic evaluation of the signaling events
regulating curcumin-mediated chemosensitization of
breast cancer cells to 5-fluorouracil
BSVinod1,2,JAntony1,2,HHNair1,VTPuliyappadamba1,MSaikia1,SShyamNarayanan1,ABevin1andRJohnAnto*,1
5-Fluorouracil(5-FU)isthefirstrationallydesignedantimetabolite,whichachievesitstherapeuticefficacythroughinhibitionof
theenzymethymidylatesynthase(TS),whichisessentialforthesynthesisandrepairofDNA.However,prolongedexposureto
5-FUinducesTSoverexpression,whichleadsto5-FUresistanceincancercells.Severalstudieshaveidentifiedcurcuminasa
potentchemosensitizeragainstchemoresistanceinducedbyvariouschemotherapeuticdrugs.In


--- 21088503.pdf ---
RESEARCH PAPER RESEARCH PAPER
Cancer Biology & Therapy 11:2, 263-276; January 15, 2011; © 2011 Landes Bioscience
Anticancer activity of celastrol in combination
with ErbB2-targeted therapeutics for treatment
of ErbB2-overexpressing breast cancers
Srikumar M. Raja,1,4,* Robert J. Clubb,1,4,† Cesar Ortega-Cava,1,4 Stetson H. Williams,1 Tameka A. Bailey,1 Lei Duan,1,4,‡
Xiangshan Zhao,3,4 Alagarasamy L. Reddi,4,¥ Abijah M. Nyong,1 Amarnath Natarajan,1 Vimla Band1,3,4 and Hamid Band1-4,*
1Eppley Institute for Research in Cancer and Allied Diseases; 2Departments of Biochemistry and Molecular Biology, Pathology and Microbiology, and Pharmacology and
Neuroscience; and 3Genetics, Cell Biology and Anatomy; College of Medicine; University of Nebraska Medical Center; Omaha, NE USA
This work was initi


--- 32872376.pdf ---
nutrients
Article
Dietary Glycine Prevents FOLFOX
Chemotherapy-Induced Heart Injury: A Colorectal
Cancer Liver Metastasis Treatment Model in Rats
JusteManeikyte1,2,AugustinasBausys1,2,3,BettinaLeber1 ,NicoleFeldbacher1,
GeraldHoefler4,DagmarKolb-Lenz5,6,KestutisStrupas2,PhilippStiegler1and
PeterSchemmer1,*
1 General,VisceralandTransplantSurgery,DepartmentofSurgery,MedicalUniversityofGraz,
8036Graz,Austria;juste.maneikyte@gmail.com(J.M.);abpelikanas@gmail.com(A.B.);
bettina.leber@medunigraz.at(B.L.);Nicole.Feldbacher@medunigraz.at(N.F.);
philipp.stiegler@medunigraz.at(P.S.)
2 FacultyofMedicine,VilniusUniversity,03101Vilnius,Lithuania;kestutis.strupas@santa.lt
3 NationalCancerInstitute,08406Vilnius,Lithuania
4 DiagnosticandResearchInstituteofPathology,MedicalUniversityofGraz,8010Graz,Austria


--- 29626307.pdf ---
HHS Public Access
Author manuscript
Ann Surg Oncol. Author manuscript; available in PMC 2019 June 01.
Published in final edited form as:
Ann Surg Oncol. 2018 June ; 25(6): 1709–1715. doi:10.1245/s10434-018-6468-8.
Preoperative fluorouracil, doxorubicin and streptozocin for the
treatment of pancreatic neuroendocrine liver metastases
Jordan M Cloyd, MD1,*, Kiyohiko Omichi, MD, PhD1,*, Takashi Mizuno, MD, PhD1, Yoshikuni
Kawaguchi, MD, PhD1, Ching-Wei D. Tzeng, MD1, Claudius Conrad, MD, PhD1, Yun Shin
Chun, MD1, Thomas A. Aloia, MD1, Matthew HG Katz, MD1, Jeffrey E Lee, MD1, Daniel
Halperin, MD2, James Yao, MD2, Jean-Nicolas Vauthey, MD1,*, and Arvind Dasari, MD2,*
1Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Gastrointestinal Medi


</observation>
**Refined Analysis:**

1.  **27980427.pdf**:
    *   **Text**: "curcumin sensitizes human gastric cancer cells to 5-fluorouracil... However, the occurrence of resistance to 5-FU treatment poses a major problem... In this study, we found that the NFkB-signaling pathway contributed to 5-FU resistance..."
    *   **Reasoning**: It explicitly mentions overcoming resistance ("resistance... poses a major problem", "contributed to 5-FU resistance"). This suggests **Type 3 (Reversing drug resistance)**.

2.  **25653233.pdf**:
    *   **Text**: "Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer"
    *   **Reasoning**: "Chemoresistant colorectal cancer". This is clearly about reversing resistance. My previous heuristic score favored Type 1 because of "chemosensitization", but the context "chemoresistant" makes it **Type 3 (Reversing drug resistance)**.

3.  **23429291.pdf**:
    *   **Text**: "Mechanistic evaluation of the signaling events regulating curcumin-mediated chemosensitization of breast cancer cells to 5-fluorouracil... prolonged exposure to 5-FU induces TS overexpression, which leads to 5-FU resistance in cancer cells. Several studies have identified curcumin as a potent chemosensitizer against chemoresistance..."
    *   **Reasoning**: Again, "chemosensitization" in the context of "chemoresistance". The abstract says 5-FU exposure leads to resistance, and curcumin is a sensitizer *against chemoresistance*. This aligns with **Type 3 (Reversing drug resistance)**.
    *   *Correction*: My previous automated score said Type 1. But reading the text, it's about resistance. However, Type 1 is "enhancing efficacy by augmenting sensitivity". Sometimes these are very close. But "reversing resistance" usually implies a specific resistant cell line or mechanism. The abstract mentions "5-FU resistance in cancer cells".
    *   Let's look closer. "Chemosensitization... to 5-FU". If the cells are not explicitly resistant *initially* but the paper studies how to prevent/overcome resistance or sensitize generally, it might be 1.
    *   However, "against chemoresistance" is strong. Let's look at the options again.
        *   (1) enhancing drug efficacy by augmenting sensitivity and achieving synergy
        *   (3) reversing drug resistance
    *   Usually, if the paper uses "resistant" cell lines, it's 3. If it uses "parental" cell lines and shows synergy, it's 1.
    *   Paper 25653233 title: "chemoresistant colorectal cancer". Definitely 3.
    *   Paper 23429291 text: "prolonged exposure... leads to resistance... curcumin as a potent chemosensitizer against chemoresistance". This implies the context is resistance. I will classify as **3**.

4.  **21088503.pdf**:
    *   **Text**: "Anticancer activity of celastrol in combination with ErbB2-targeted therapeutics... synergistic growth inhibition...".
    *   **Reasoning**: "Combination", "Synergistic". No major mention of "resistance" in the first few lines compared to "synergy". This is likely **Type 1 (Enhancing efficacy/Synergy)**.

5.  **32872376.pdf**:
    *   **Text**: "Dietary Glycine Prevents FOLFOX Chemotherapy-Induced Heart Injury".
    *   **Reasoning**: "Prevents Heart Injury". Toxicity. **Type 2 (Decreasing adverse drug reactions)**.

6.  **29626307.pdf**:
    *   **Text**: "Preoperative fluorouracil, doxorubicin and streptozocin for the treatment of pancreatic neuroendocrine liver metastases".
    *   **Reasoning**: This is a clinical study of a regimen. Is there a "natural product"? "Streptozocin" is a glucosamine-nitrosourea (derived from Streptomyces). "Doxorubicin" (Streptomyces). These are standard chemos. Is there a specific *combination* focus? The task description says "natural product-based drug combination".
    *   Let's check the paper content for what the "combination" is and its effect.
    *   Wait, is this a negative control or a specific case?
    *   Let's re-read the snippet in the log. "Preoperative fluorouracil, doxorubicin and streptozocin...".
    *   Let's search for keywords in the full text of 29626307.pdf using python to be sure. It might be about toxicity or efficacy.
    *   Actually, let's look at the prompt again. "natural product-based drug combination".
    *   This paper might be about the *efficacy* of this combination (Type 1) or *toxicity* (Type 2).
    *   Let's read the conclusion of 29626307.

<execute>
import pdfplumber
import os

filepath = "benchmark/dataset/NPCDR/29626307.pdf"
with pdfplumber.open(filepath) as pdf:
    text = ""
    for page in pdf.pages:
        text += page.extract_text()

print(text[-2000:]) # Read the end of the paper for Conclusion</execute>
<observation>Figure 4.
Overall survival among patients with pancreatic neuroendocrine liver metastases treated with
FAS and surgery (green), surgery without FAS (red), or FAS without surgery (blue).
Ann Surg Oncol. Author manuscript; available in PMC 2019 June 01.
Author
Manuscript
Author
Manuscript
Author
Manuscript
Author
ManuscriptAuthor
Manuscript
Author
Manuscript
Author
Manuscript
Author Manuscript
Cloyd et al. Page 14
1 elbaT
sesatsatem
revil
enircodneoruen
citaercnap
htiw
stneitap
fo
semoctuo
dna
scitsiretcarahc
cigolohtapocinilC
trohoC
lacideM
trohoC
lacigruS
2eulav
P
stneitaP
llA
1eulav
P
SAF
evitarepoerP
SAF
evitarepoerP
oN
stneitaP
llA
)42=n(
)72=n(
)04=n(
)76=n(
866.0
9:51
471.0
9:81
02:02
92:83
)F :M( redneG
331.0
)67–24(
06
449.0
)47–92(25
)67–11(
65
)67–11(
65
)egnar(
sraey ,egA naideM
919.0
)15–91(
82
204.0
)3.14–7.81(
5.72
)5.64–5.31(9.52
)5.64–5.31(4.62
)egnar(
)2m/gk(
xedni
ssam ydoB naideM
010.0
11–1/12/3
817.0
01–1/51/21
51–1/42/61
51–1/93/82
egnaR/elpitluM/yratiloS
,sromut fo rebmuN
300.0
)251–01(
24
100.0
)721–01(
63
)121–3(
12
)721–3(
13
)egnar(
mm
,romuT
tsegraL
fo eziS naideM
411.0
4/02
1000.<
1/62
02/02
12/64
suonorhcateM
/ suonorhcnyS
610.0
)%97(
91
351.0
)%44(
21
)%82(
11
)%43(
32
noitacol
romut laretaliB
210.0
3/0/3/81
260.0
7/0/11/9
41/4/6/61
12/4/71/52
nwonknu/3G/2G/1G
edarG
135.0
)01–2(
6
953.0
)02–9.1(
5
)53–1(
01
)53–1(
8.5
)egnar(
xednI 76 iK naideM
979.0
)%22(
6
)%32(
9
)%22(
51
noitceser rojaM
403.0
)%11(
3
)%12(
8
)%61(
11
AFR htiw noitceseR
962.0
)%03(
8
)%81(
7
)%22(
51
noitceser
1R
A/N
617.0
)%62(
7
)%03(
21
)%82(
91
snoitacilpmoc
evitarepotsop rojaM
980.0
1/0/42/1/1
6/1/42/8/1
7/1/84/9/2
nwonknu/4T/3T/2T/1T
,egats T yramirP
130.0
1/91/7
5/61/91
6/53/62
nwonknu/1N/0N
,egats N yramirP
.denoitnem
esiwrehto
sselnu
)%(
rebmun era stluseR
1
;yregrus
+
SAF
on
susrev
yregrus
+
SAF
ohw
stneitap
gnirapmoc eulaV
p 2
enola
SAF
susrev
yregrus
+
SAF
deviecer
ohw
stneitap
fo nosirapmoC
Ann Surg Oncol. Author manuscript; available in PMC 2019 June 01.
</observation>
The text extraction for the table is messy (reversed text), but let's look at the "Conclusions" or "Abstract" again.
I'll read the first page of 29626307.pdf again, but this time a bit more.

<execute>
import pdfplumber
import os

filepath = "benchmark/dataset/NPCDR/29626307.pdf"
with pdfplumber.open(filepath) as pdf:
    print(pdf.pages[0].extract_text())
    print("\n--- Page 2 ---")
    print(pdf.pages[1].extract_text())</execute>
<observation>HHS Public Access
Author manuscript
Ann Surg Oncol. Author manuscript; available in PMC 2019 June 01.
Published in final edited form as:
Ann Surg Oncol. 2018 June ; 25(6): 1709–1715. doi:10.1245/s10434-018-6468-8.
Preoperative fluorouracil, doxorubicin and streptozocin for the
treatment of pancreatic neuroendocrine liver metastases
Jordan M Cloyd, MD1,*, Kiyohiko Omichi, MD, PhD1,*, Takashi Mizuno, MD, PhD1, Yoshikuni
Kawaguchi, MD, PhD1, Ching-Wei D. Tzeng, MD1, Claudius Conrad, MD, PhD1, Yun Shin
Chun, MD1, Thomas A. Aloia, MD1, Matthew HG Katz, MD1, Jeffrey E Lee, MD1, Daniel
Halperin, MD2, James Yao, MD2, Jean-Nicolas Vauthey, MD1,*, and Arvind Dasari, MD2,*
1Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer
Center, Houston, TX, USA
Abstract
Introduction—While preoperative chemotherapy is frequently utilized prior to resection of non-
neuroendocrine liver metastases, patients with resectable neuroendocrine liver metastases typically
undergo surgery first. FAS is a cytotoxic chemotherapy regimen that is associated with substantial
response rates in locally advanced and metastatic pancreatic neuroendocrine tumors.
Methods—All patients who underwent R0/R1 resection of pancreatic neuroendocrine liver
metastases at a single institution between 1998 and 2015 were included. The outcomes of patients
treated with preoperative FAS were compared to those of patients who were not.
Results—Of the 67 patients included, 27 (40.3%) received preoperative FAS while 40 (59.7%)
did not. Despite being associated with higher rates of synchronous disease, lymph node
metastases, and larger tumor size, patients who received preoperative FAS had similar overall
survival (OS, 108.2 months [95% CI 78.0-136.0] vs 107.0 months [95% CI 78.0-136.0], p=0.64)
and recurrence-free survival (RFS, 25.1 months [95% CI 23.2-27.0] vs 18.0 months [95% CI
13.8-22.2], p=0.16) as patients who did not. Among patients who presented with synchronous liver
metastases (n=46), the median OS (97.3 months [95% CI 65.9-128.6] vs 65.0 months [95% CI
28.1-101.9], p=0.001) and RFS (24.8 months [95% CI 22.6-26.9] vs 12.1 months [2.2-22.0],
p=0.003) were significantly greater among patients who received preoperative FAS compared to
those who did not.
Conclusions—The use of FAS prior to liver resection is associated with improved OS compared
to surgery alone among patients with advanced synchronous pancreatic neuroendocrine liver
metastases.
Corresponding authors: Jean-Nicolas Vauthey, MD, FACS, Department of Surgical Oncology, The University of Texas MD
Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1484, Houston, TX 77030, USA, jvauthey@mdanderson.org; Arvind
Dasari, MD, MS, Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center 1515
Holcombe Blvd, Unit 426, Houston, TX 77030, adasari@mdanderson.org.
*These authors contributed equally to this work.
Conflicts of Interest and Source of Funding: None of the authors have any conflicts of interest associated with this study.
Author
Manuscript
Author
Manuscript
Author
Manuscript
Author
Manuscript

--- Page 2 ---
Cloyd et al. Page 2
Introduction
Pancreatic neuroendocrine tumors (pNET) are heterogeneous in both their clinical
presentation and behavior1. Although the clinical course of low and intermediate grade
pNETs is believed to be indolent, as many as 40% of patients with pNETs will develop
neuroendocrine liver metastases (NELM) during their lifetime2. Although the presence of
liver metastases is one of the strongest negative prognostic indicators in patients with pNET,
surgical resection of NELM, when possible, is associated with a significant survival
benefit3,4. In fact, a meta-analysis reported a pooled median 5 year overall survival (OS) rate
of 71% in patients who underwent liver resection and >95% experienced symptomatic
relief5. Other liver-directed therapies include radiofrequency ablation, transarterial embolic
therapy, and most recently, peptide receptor radionuclide therapy, but liver resection is
typically associated with the best long term outcomes and is considered the first choice for
management of NELM6.
Most patients with liver metastases of non-neuroendocrine origin receive multimodality
therapy that includes systemic chemotherapy as a component of the treatment strategy. The
aims of preoperative chemotherapy include the potential to stimulate tumor downstaging, the
opportunity to assess response of the tumor to therapy, and to ensure stable tumor biology
prior to undergoing major surgery. In patients with advanced colorectal liver metastases, for
example, the combination of perioperative 5-flourouracil (5-FU) based chemotherapy and
liver resection at experienced centers is associated with excellent survival outcomes7,8.
Furthermore, perioperative systemic chemotherapy is frequently used prior to liver resection
in other cancers as well in order to select for patients with disease stability and improve
survival rates9. However, a similar role for preoperative chemotherapy in NELM secondary
to pNETs has not been previously reported.
Streptozocin was the first therapy approved for patients with advanced or symptomatic
pNET10. Since then, investigators have reported on its improved efficacy when combined
with 5-FU11 and doxorubicin12. At the University of Texas MD Anderson Cancer Center, we
have observed response rates of over 40% among patients with locally advanced and
metastatic pNET when treated with combination 5-fluorouracil, doxorubicin and
streptozocin (FAS)13,14. Recently, we evaluated our experience with preoperative FAS in
patients with non-metastatic locally advanced well-differentiated pNETs and found that FAS
was infrequently associated with significant tumor downstaging suggesting differential
effects of chemotherapy on the primary vs metastatic tumors15. The role of preoperative FAS
in patients with advanced NELM, with or without the primary pNET in situ, has not been
previously explored. Within this context, we set out to evaluate the influence of preoperative
FAS on the outcomes of patients with pancreatic NELM who underwent liver resection.
MATERIAL AND METHODS
Patients Selection
The Institutional Review Board of MD Anderson Cancer Center approved this retrospective
study (PA17-0318). From a prospectively maintained database, we included all patients who
underwent liver resection for NELM of pancreatic origin between January 1998 and
Ann Surg Oncol. Author manuscript; available in PMC 2019 June 01.
Author
Manuscript
Author
Manuscript
Author
Manuscript
Author
Manuscript
</observation>
**Refined Analysis for 29626307.pdf**:
*   **Abstract**: "The use of FAS prior to liver resection is associated with improved OS compared to surgery alone among patients with advanced synchronous pancreatic neuroendocrine liver metastases."
*   **Context**: FAS = Fluorouracil, Doxorubicin, Streptozocin.
*   **Effect**: Improved OS (Overall Survival) and RFS (Recurrence-Free Survival). It compares FAS + Surgery vs Surgery alone.
*   **Category Selection**:
    *   (1) enhancing drug efficacy by augmenting sensitivity and achieving synergy: The combination (FAS) improves survival compared to surgery alone. Is it "enhancing drug efficacy"? It is showing the efficacy *of the combination*. The prompt asks about "enhancing drug efficacy by augmenting sensitivity and achieving synergy". Usually this implies Drug A + Drug B is better than Drug A. Here it's FAS + Surgery vs Surgery.
    *   However, let's look at the drug combination itself: FAS. It's a known regimen. The paper evaluates "Preoperative FAS".
    *   Is there any mention of reducing toxicity? No, it mentions "associated with improved OS".
    *   Is there any mention of reversing resistance? No.
    *   Is it enhancing efficacy? Yes, "improved OS". The combination of drugs (FAS) + Surgery is effective.
    *   Let's check if FAS itself is the "combination" being analyzed for synergy. The paper cites previous work (refs 11, 12) for FAS synergy. This paper tests the *clinical benefit* of Pre-op FAS.
    *   Usually, if the result is "improved survival" or "tumor reduction", it falls under Category 1 (Enhancing efficacy).
    *   Also, the prompt mentions "natural product-based drug combination". Streptozocin and Doxorubicin are natural products (antibiotics). 5-FU is synthetic. This fits.
    *   Therefore, **Type 1** seems the most appropriate among the choices. It's definitely not 2 (toxicity) as the abstract doesn't highlight safety/toxicity reduction as the *primary* finding (it focuses on survival). It's not 3 (resistance) as it doesn't discuss chemoresistance reversal.

**Summary of Types:**
*   27980427: Type 3 (Reversing drug resistance) - "Curcumin sensitizes... to 5-FU through inhibition of NFkB... contributed to 5-FU resistance"
*   25653233: Type 3 (Reversing drug resistance) - "Curcumin mediates chemosensitization... in chemoresistant colorectal cancer"
*   23429291: Type 3 (Reversing drug resistance) - "Curcumin... potent chemosensitizer against chemoresistance".
*   21088503: Type 1 (Enhancing efficacy) - "Anticancer activity... in combination... synergistic growth inhibition"
*   32872376: Type 2 (Decreasing adverse reactions) - "Prevents... Heart Injury"
*   29626307: Type 2 or 1?
    *   Wait, let's re-evaluate 29626307.
    *   My automated score for 29626307 was: T1=3, T2=7, T3=0. It favored Type 2 slightly.
    *   Why? Maybe keywords like "safety", "complications"?
    *   Abstract: "patients who received preoperative FAS had similar... complications... as patients who did not."
    *   It's not *decreasing* adverse reactions. It's just checking if it's safe.
    *   The primary *positive* result is "Improved OS". This is efficacy.
    *   Let me check if there is another angle. Is it possible that the prompt considers "Decreasing adverse drug reactions" to include "Surgery + Drug vs Surgery" where the drug reduces the risk of *recurrence* (adverse event)? No, usually "adverse drug reactions" means toxicity.
    *   Therefore, 29626307 should be **Type 1**.

Wait, let me double check 23429291. "Mechanistic evaluation of the signaling events regulating curcumin-mediated chemosensitization of breast cancer cells to 5-fluorouracil".
Abstract: "5-FU induces TS overexpression, which leads to 5-FU resistance... curcumin as a potent chemosensitizer against chemoresistance".
This explicitly frames the problem as "chemoresistance". So **Type 3** is correct.

Let me double check 29626307.
Is it possible the task implies "natural product" (e.g. curcumin) + "drug"?
In 29626307, the drugs are Fluorouracil, Doxorubicin, Streptozocin.
Streptozocin is a natural product (from *Streptomyces achromogenes*). Doxorubicin is a natural product (anthracycline).
The combination is FAS.
Is the paper about *toxicity*? The title is "Preoperative fluorouracil... for the treatment of...".
Abstract Conclusion: "associated with improved OS".
So it is **Type 1**.

However, looking at the provided Example Output:
"15380427": 2, "25653532": 1.
These are just random/different PMIDs.
My classification seems robust.

One final check on 32872376: "Dietary Glycine Prevents FOLFOX Chemotherapy-Induced Heart Injury". Glycine is a natural product (amino acid). It reduces toxicity (Heart Injury). **Type 2**. Correct.

One final check on 21088503: "Celastrol... in combination with ErbB2-targeted therapeutics". Celastrol is a triterpene (natural). "Synergistic growth inhibition". **Type 1**. Correct.

One final check on 27980427: "Curcumin... sensitizes... to 5-FU... inhibition of NFkB... resistance". **Type 3**. Correct.

One final check on 25653233: "Curcumin... chemoresistant colorectal cancer". **Type 3**. Correct.

One final check on 29626307: "FAS... improved OS". **Type 1**.

Wait, I have 3 PMIDs with Type 3, 2 PMIDs with Type 1, 1 PMID with Type 2?
Let's list them:
*   27980427: 3
*   25653233: 3
*   23429291: 3
*   21088503: 1
*   32872376: 2
*   29626307: 1

Is there any nuance I missed for 29626307?
"Preoperative FAS...".
Maybe "Decreasing adverse reactions"?
Does it say FAS reduces the toxicity of Surgery? No.
Does it say Surgery reduces the toxicity of FAS? No.
Does it say FAS reduces the toxicity of 5-FU? No.
It says FAS improves survival. **Type 1**.

Is there any nuance for 23429291?
"Curcumin-mediated chemosensitization...".
If the cells were *not* resistant to start with, but Curcumin made them *more* sensitive, it is Type 1.
If the cells *were* resistant (or resistance was induced), and Curcumin reversed it, it is Type 3.
Abstract: "However, prolonged exposure to 5-FU induces TS overexpression, which leads to 5-FU resistance... curcumin as a potent chemosensitizer against chemoresistance... We found that curcumin downregulated TS...".
This implies the mechanism is preventing/reversing the resistance mechanism (TS overexpression).
So **Type 3** is better.

Final List:
*   27980427: 3
*   25653233: 3
*   23429291: 3
*   21088503: 1
*   32872376: 2
*   29626307: 1

Wait, let me check 29626307 one more time. Is it possible that "Doxorubicin" or "Streptozocin" *is* the natural product and it's being combined with 5-FU? Yes.
Is the paper about "Decreasing adverse drug reactions"? The snippet showed scores T1=3, T2=7.
Why was T2 higher?
Snippet: "snoitacilpmoc evitarepotsop rojaM" (Major postoperative complications).
The paper discusses complications (toxicity of surgery).
"patients who received preoperative FAS had similar overall survival... and recurrence-free survival... as patients who did not [in the whole group]."
Wait, the Abstract says: "patients who received preoperative FAS had similar... OS... as patients who did not." (p=0.64)
BUT "Among patients who presented with synchronous liver metastases... median OS... were significantly greater...".
So for a subgroup, it improved Efficacy.
Also "Despite being associated with higher rates of...".
Did it reduce complications? Table says "Major postoperative complications... 26% vs 30%". Not significant.
So it's not a toxicity reduction paper. It's an efficacy paper (for synchronous metastases).
So **Type 1** stands.

Let's prepare the final JSON.

1. [✓] Create the intermediate directory.
2. [✓] Locate the PDF files.
3. [✓] Read the text content from each of the 6 PDF files.
4. [✓] Analyze the text of each paper to determine the primary therapeutic effect.
5. [ ] Construct the final JSON list.
6. [ ] Save the JSON list.

<execute>
import json
import os

results = [
    {"PMID": "27980427", "TypeID": 3},
    {"PMID": "25653233", "TypeID": 3},
    {"PMID": "23429291", "TypeID": 3},
    {"PMID": "21088503", "TypeID": 1},
    {"PMID": "32872376", "TypeID": 2},
    {"PMID": "29626307", "TypeID": 1}
]

output_dir = "/root/autodl-tmp/biomni_v20260208_pred_results/gemini-3-pro-preview/"
output_file = os.path.join(output_dir, "npcdr_extract_1.json")

os.makedirs(output_dir, exist_ok=True)

with open(output_file, 'w') as f:
    json.dump(results, f, indent=4)

print(f"Results saved to {output_file}")
print(json.dumps(results, indent=4))</execute>
<observation>Results saved to /root/autodl-tmp/biomni_v20260208_pred_results/gemini-3-pro-preview/npcdr_extract_1.json
[
    {
        "PMID": "27980427",
        "TypeID": 3
    },
    {
        "PMID": "25653233",
        "TypeID": 3
    },
    {
        "PMID": "23429291",
        "TypeID": 3
    },
    {
        "PMID": "21088503",
        "TypeID": 1
    },
    {
        "PMID": "32872376",
        "TypeID": 2
    },
    {
        "PMID": "29626307",
        "TypeID": 1
    }
]
</observation>
I have analyzed the papers and generated the JSON output.

Paper Summary:
- 27980427: Curcumin sensitizes... contributes to 5-FU resistance. -> Reversing Resistance (3)
- 25653233: Curcumin... in chemoresistant colorectal cancer. -> Reversing Resistance (3)
- 23429291: Curcumin... against chemoresistance. -> Reversing Resistance (3)
- 21088503: Celastrol... synergistic growth inhibition. -> Enhancing Efficacy (1)
- 32872376: Glycine Prevents... Heart Injury. -> Decreasing Adverse Reactions (2)
- 29626307: FAS (Preoperative)... improved OS. -> Enhancing Efficacy (1)

The output is saved. I'll print the content of the saved file to be absolutely sure.

<execute>
#!BASH
cat /root/autodl-tmp/biomni_v20260208_pred_results/gemini-3-pro-preview/npcdr_extract_1.json</execute>
<observation>[
    {
        "PMID": "27980427",
        "TypeID": 3
    },
    {
        "PMID": "25653233",
        "TypeID": 3
    },
    {
        "PMID": "23429291",
        "TypeID": 3
    },
    {
        "PMID": "21088503",
        "TypeID": 1
    },
    {
        "PMID": "32872376",
        "TypeID": 2
    },
    {
        "PMID": "29626307",
        "TypeID": 1
    }
]</observation>
The task is complete. I have classified the therapeutic effects of the natural product-based drug combinations in the provided literature and saved the results in the required JSON format.

1. [✓] Create the intermediate directory.
2. [✓] Locate the PDF files.
3. [✓] Read the text content from each of the 6 PDF files.
4. [✓] Analyze the text of each paper to determine the primary therapeutic effect.
5. [✓] Construct the final JSON list.
6. [✓] Save the JSON list.

The results are saved at `/root/autodl-tmp/biomni_v20260208_pred_results/gemini-3-pro-preview/npcdr_extract_1.json`.

<solution>
[
    {
        "PMID": "27980427",
        "TypeID": 3
    },
    {
        "PMID": "25653233",
        "TypeID": 3
    },
    {
        "PMID": "23429291",
        "TypeID": 3
    },
    {
        "PMID": "21088503",
        "TypeID": 1
    },
    {
        "PMID": "32872376",
        "TypeID": 2
    },
    {
        "PMID": "29626307",
        "TypeID": 1
    }
]</solution>